New York City, July 14, 2020 — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE:BETR) (OTCQB:BETRD) (FRA: BLife Therapeutics BLife TherapeuticsNPAT) indicated the finalisation of its rebranding exercise for its wholly owned subsidiary, BLife Therapeutics, which has been publicly formalised through the launching of its new website. Following its announcement regarding the merger with Altum Pharma, the Company’s name and branding is now more consistent with its intent to become a major player within the biotechnology space.
The new website, http://www.blifetherapeutics.com, provides visitors with an overview of the Company’s treatment development pipeline, including information on the trial Phases for each of the treatments.
The current pipeline for the Company includes:
Coronavirus Treatment – AP-003
Patent pending proprietary Interferon α2b (IFNa2b) inhalation formulation. In recent findings, IFNa2b has been shown to be effective in slowing viral replication. Not only did IFNa2b help patients’ immune systems clear the coronavirus faster, it also seemed to reduce certain inflammatory proteins linked to severe COVID-19 complications.
Anti-bone cancer – AP-002
AP-002 is unique in that it has both anti-bone resorption and direct anti-tumour cell killing activity. This positions it ideally to treat cancer metastatic to the bone. Bone metastases often result in severe pain, spinal cord compression and cancer-induced bone fractures, collectively referred to as skeletal related events (SREs).
AP-002 has US FDA IND approval and started Phase 1-2 trials in October 2019 in the US with cancer patients who have advanced or recurrent solid tumours.
Human Papilloma Virus (HPV) – AP-001. Phase 2 Completed.
AP-001 is a topical IFNa2b product for the treatment of HPV infection that can cause cervical cancer. Interferon alpha-2b is already established as a potent, broad acting anti-viral agent, with established anti-HPV activity. The Company has acquired the Altum’s BiPhasix™ technology which is a unique encapsulation and delivery platform technology.
BiPhasix-encapsulated interferon IFNa2b can be topically applied and self-administered for use in treatment of HPV-cervical dysplasia. Currently treatment is via painful injections within medical settings.
Disclosure: BetterLife Pharma is a client of BDA International.
About BDA International, Inc.:
BDA International is an independent global firm offering a wide range of IR and PR related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including BETRF. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and BETRF may do so via the contact information at the bottom of this release.
Disclaimer
The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. BetterLife Pharma is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.
Investor Relations Contact:
Dost Mushtaq
BDA International
www.bda-ir.com
[email protected]
Attachment